> Canada's Response Biomedical has raised $12 million in financing for its diagnostic testing business and added five former officers and directors of ID Biomedical to its board of directors. Release
> The FDA has issued an approvable letter for Prestwick Pharmaceuticals' Xenazine as a treatment for chorea associated with Huntington's disease. Release
> The FDA has approved Astellas Pharma's Prograf for the prevention of rejection of a heart transplant. Release
> Cardiome Pharma has announced that its development partner Astellas has submitted an NDA to the FDA for RSD1235, an investigational new drug for the acute conversion of atrial fibrillation. Report
> Banca Intesa has increased its stake in Italy's Sigma-tau to about 5 percent. Report
And Finally…The data doesn't look good for patients who rely on the power of other people's prayers. Article